Compare VLRS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | ANNX |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.9M | 726.1M |
| IPO Year | 2013 | 2020 |
| Metric | VLRS | ANNX |
|---|---|---|
| Price | $5.72 | $3.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $9.04 | ★ $15.43 |
| AVG Volume (30 Days) | 383.6K | ★ 3.4M |
| Earning Date | 10-26-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.91 | N/A |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.59 | $2.54 |
| 52 Week High | $10.80 | $7.18 |
| Indicator | VLRS | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 44.05 |
| Support Level | N/A | $3.71 |
| Resistance Level | $7.15 | $4.37 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 14.71 | 47.12 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.